Darbepoetin for the treatment of anemia of myelodysplastic syndromes: efficacy and quality of life

被引：0
|
作者：
Oliva, E. N.
Latagliata, R.
Danova, M.
Specchia, G.
Impera, S.
Rovati, B.
Vincelli, I.
Liso, V.
Alimena, G.
Ronco, F.
Carmosino, I.
Risitano, A.
Breccia, M.
Nobile, F.
机构：
[1] Hematol Unit, Az Osp BMM Reggio Calabria, Calabria, Italy
[2] Univ Roma La Sapienza, Dept Hematol, Rome, Italy
[3] Univ S Matteo, Cytometry & Cellular Therapies Unit, Pavia, Italy
[4] Studi Bari Univ, Cattedra Serv Ematol, Bari, Italy
[5] Az Osp, Oncohematol Unit, Catania, Italy
[6] Univ Naples Federico II, Inst Hematol, Naples, Italy
来源：
LEUKEMIA RESEARCH | 2007年 / 31卷
关键词：
D O I：
10.1016/S0145-2126(07)70212-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S117 / S118
页数：2
相关论文
共 50 条
  • [21] Costs and quality of life in patients with myelodysplastic syndromes
    Lucioni, Carlo
    Finelli, Carlo
    Mazzi, Silvio
    Oliva, Esther N.
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2013, 3 (03): : 246 - 259
  • [22] Darbepoetin efficacy in myelodysplastic syndrome.
    Oliva, EN
    Ronco, F
    Danova, M
    Rovati, B
    Dimitrov, BD
    Vincelli, L
    Alati, C
    Nobile, F
    BLOOD, 2004, 104 (11) : 260B - 260B
  • [23] The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 805 - 810
  • [24] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    BLOOD, 2008, 112 (11) : 1184 - 1184
  • [25] Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis
    Park, Sophie
    Fenaux, Pierre
    Greenberg, Peter
    Mehta, Bhakti
    Callaghan, Fiona
    Kim, Christopher
    Tomita, Dianne
    Xu, Hairong
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (05) : 730 - 747
  • [26] THE TREATMENT OF ANEMIA IN THE MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BOWEN, D
    CULLIGAN, D
    JACOBS, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) : 419 - 423
  • [27] BIOSIMILAR EPOETIN ZETA FOR THE TREATMENT OF ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
    Pelizzari, A.
    Ferrero, D.
    Molteni, A.
    Allione, B.
    Mezzabotta, M.
    Clavio, M.
    Borlenghi, E.
    Rossi, G.
    Masiera, E.
    Santini, V.
    LEUKEMIA RESEARCH, 2015, 39 : S56 - S57
  • [28] Treatment of anemia of myelodysplastic syndromes and improvements in cardiac geometry.
    Oliva, Esther N.
    Benedetto, Frank
    Specchia, Giorgina
    Vincelli, Iolanda
    Colonna, Paolo
    Liso, Vincenzo
    Fortugno, Francesco
    Nobile, Francesco
    BLOOD, 2006, 108 (11) : 294B - 294B
  • [29] Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes
    Konstantinidou, P
    Repoussis, P
    Georgopoulos, A
    Tsiara, S
    Bai, M
    Christou, L
    Bourantas, K
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1036 - 1036
  • [30] Association of amifostine and erythropoietin for the treatment of anemia in myelodysplastic syndromes.
    Musto, P
    Grossi, A
    Balestri, F
    Scalzulli, PR
    D'Arena, G
    Sanpaolo, MG
    Mantuano, SF
    Bodenizza, CA
    Falcone, A
    Rossi-Ferrini, P
    Carotenuto, M
    BLOOD, 2000, 96 (11) : 262B - 262B
12345